人羊膜上皮干细胞(Shanghai iCELL Biotechnology)(Human amniotic epithelial stem cells(Shanghai iCELL Biotechnology)) - 在研适应症：宫腔粘连，帕金森病，原发性卵巢功能不全_专利_临床

概要

基本信息

药物类型

干细胞疗法

别名

hAECs(Shanghai iCELL Biotechnology)、hAESCs(Shanghai iCELL Biotechnology)

靶点-

作用机制

干细胞替代物

治疗领域

免疫系统疾病神经系统疾病内分泌与代谢疾病+ [4]

在研适应症

宫腔粘连帕金森病原发性卵巢功能不全+ [8]

非在研适应症-

原研机构

上海赛傲生物技术有限公司

在研机构

上海赛傲生物技术有限公司

非在研机构

北京大学人民医院

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

14

项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的临床试验

ChiCTR2400082783 / Suspended临床1期IIT

A dose-finding trial of human amniotic epithelial stem cells for the treatment of acute kidney injury in critically ill patients

开始日期2024-05-01

申办/合作机构

北京大学第一医院

CTR20233586 / Recruiting临床1期

人羊膜上皮干细胞（hAESCs）注射液治疗造血干细胞移植后难治性急性移植物抗宿主病（aGVHD）的I 期临床研究，主要目的评价hAESCs注射液治疗造血干细胞移植后难治性aGVHD受试者的安全性和耐受性。

主要目的：评价hAESCs注射液治疗造血干细胞移植后难治性aGVHD受试者的安全性和耐受性。次要目的：1、初步评价hAESCs注射液治疗造血干细胞移植后难治性aGVHD受试者的疗效； 2、初步评价hAESCs注射液治疗造血干细胞移植后难治性aGVHD受试者的药代动力学（PK）特征； 3、初步评价hAESCs注射液治疗造血干细胞移植后难治性aGVHD受试者的免疫原性。

开始日期2024-02-19

申办/合作机构

上海赛傲生物技术有限公司

NCT06164288 / Not yet recruiting临床1期

A Phase I Study to Evaluate the Safety and Efficacy of Human Amniotic Epithelial Stem Cell（hAESCs）Injection Treatment for the Patients With Refractory aGVHD After Allogeneic Hematopoietic Cell Transplantation (HCT)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a process in which hematopoietic stem cells from a donor are injected into the recipient's body, are the treatment of choice for many hematologic malignancies. Graft-versus-host disease (GVHD) is a common and important complication after allogeneic HSCT. GVHD is a major obstacle to the success of HSCT treatment and a leading cause of death after HSCT treatment.
Hormone therapy is currently the standard treatment for aGVHD, i.e., the first-line treatment. However, 40%
50% of aGVHD cannot be controlled by hormone therapy, and additional therapeutic intervention is required. According to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for hematopoietic stem cell transplantation - pre-transplant recipient evaluation and management of GVHD (2021.V3), the recommended drugs for second-line treatment of grade II
IV aGVHD include: alemtuzumab, α-1 antitrypsin, antithymocyte globulin, basiliximab, calcineurin inhibitors, etanercept, extracorporeal photopheresis replacement therapy, infliximab, mammalian rapamycin target protein inhibitors, mycophenolate mofetil, Pentostatin, ruxolitinib, tocilizumab. Second-line treatment is based on retrospective data and there is no standard salvage therapy, which is reflected in the inconsistent treatment strategy for aGVHD across transplant centers.
One of the biological functions of hAESCs in amniotic membranes in vivo is to exert reproductive immunomodulatory effects and protect the fetus from rejection by the maternal immune system, so hAESCs have natural immunomodulatory functions. hAESCs have significant inhibitory effects on T cells, antigen-presenting cells (APCs), natural killer (NK) cells, macrophages, neutrophils, B cells and other immune cells associated with organ damage during the pathogenesis of aGVHD, and hAESCs have great potential in the treatment of aGVHD. Therefore, the sponsor developed hAESCs injections intended for the treatment of aGVHD.
The experimental drug in this study is hAESCs injection, which is intended to be used for the treatment of adult patients with grade III.
IV. refractory aGVHD after hematopoietic stem cell transplantation, and to explore the safety and preliminary efficacy of its treatment.

开始日期2024-01-01

申办/合作机构

上海赛傲生物技术有限公司

100 项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的临床结果

登录后查看更多信息

100 项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的转化医学

登录后查看更多信息

100 项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的专利（医药）

登录后查看更多信息

57

项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的文献（医药）

2024-10-14·Biology of Reproduction

Human amniotic epithelial cells improve uterine spiral artery remodeling to ameliorate preeclampsia in a rat model

Article

作者: Han, Ting-Li ; Geng, Lanxin ; Dong, Xiaojing ; Zhang, Guanghui ; Zhong, Xiaocui ; Zhou, Yanqiu ; Qin, Zuchao

AbstractPreeclampsia (PE) is a multisystem pregnancy disorder characterized by impaired remodeling of placental spiral arteries, which leads to the release of pro-inflammatory cytokines and anti-angiogenic agents. However, treatment options for PE are limited, with termination of pregnancy being the only curative option. In this work, we investigated the effects of human amniotic epithelial cells (hAECs) in PE rat model. The rats were induced with lipopolysaccharide (LPS) on gestational day 14.5 followed by injection of hAECs and human umbilical cord mesenchymal stem cells 24 h later. The hAECs treatment resulted in a reduction in blood pressure and proteinuria in the PE rat model. Furthermore, hAECs treatment decreased levels of pro-inflammatory cytokines, reduced inflammatory cells aggregation, and alleviated the damage to placental spiral arteries by downregulating the expression of anti-angiogenic factor and upregulating proangiogenic factor. In vitro experiments confirmed that hAECs treatment restored the proliferation, migration, and angiogenesis of LPS-damaged human umbilical vein endothelial cells. Additionally, hAECs treatment had positive effects on fetal weight and neurological development in the PE group, with no negative effects on the physical development or fertility of offspring rats. These results suggested that hAECs transplantation may be a novel adjuvant therapeutic strategy for PE by reducing the inflammatory and enhancing placental spiral artery angiogenesis.

2024-08-01·Stem Cell Reviews and Reports

Human Amniotic Epithelial Stem Cells Alleviate Autoimmune Premature Ovarian Insufficiency in Mice by Targeting Granulosa Cells via AKT/ERK Pathways

Article

作者: Ni, Feida ; Chen, Jianpeng ; Ying, Yanyun ; Zhao, Wei ; Ye, Xiaohang ; Zhang, Dan ; Wang, Feixia ; Liu, Yifeng ; Lin, Yifeng ; Shen, Xuezhi ; Yu, Xiaoming

AbstractAutoimmune factors play an important role in premature ovarian insufficiency (POI). Human amniotic epithelial stem cells (hAESCs) have recently shown promising treatment effects on chemotherapy-induced POI. However, the therapeutic efficacy and underlying mechanisms of hAESCs in autoimmune POI remain to be investigated. In this study, we showed for the first time that intravenous transplantation of hAESCs could reside in the ovary of zona pellucida 3 peptide (pZP3) induced autoimmune POI mice model for at least 4 weeks. hAESCs could improve ovarian function and fertility, alleviate inflammation and reduce apoptosis of granulosa cells (GCs) in autoimmune POI mice. The transcriptome analysis of mice ovaries and in vitro co-cultivation experiments suggest that activation of the AKT and ERK pathways may be the key mechanism in the therapeutic effect of hAESCs. Our work provides the theoretical and experimental foundation for optimizing the administration of hAESCs, as well as the clinical application of hAESCs in autoimmune POI patients.Graphical Abstract

2023-11-01·Advanced Science

A 3D‐Printed Dual Driving Forces Scaffold with Self‐Promoted Cell Absorption for Spinal Cord Injury Repair

Article

作者: Qiu, Chen ; Ge, Zhen ; Yuan, Weixin ; Zhang, Shaomin ; Sun, Yuan ; He, Yong ; Liu, Jia ; Liu, He ; Xu, Yuchen ; Qiu, Cong ; Yu, Luyang ; Li, Jinying ; Yu, Kang ; Jiang, Tuoying ; Cui, Wenyu ; Zhou, Jiayi ; Jiang, Yuanqing ; He, Zhiying ; Kou, Yaohui ; Wang, Guanghao

AbstractStem cells play critical roles in cell therapies and tissue engineering for nerve repair. However, achieving effective delivery of high cell density remains a challenge. Here, a novel cell delivery platform termed the hyper expansion scaffold (HES) is developed to enable high cell loading. HES facilitated self‐promoted and efficient cell absorption via a dual driving force model. In vitro tests revealed that the HES rapidly expanded 80‐fold in size upon absorbing 2.6 million human amniotic epithelial stem cells (hAESCs) within 2 min, representing over a 400% increase in loading capacity versus controls. This enhanced uptake benefited from macroscopic swelling forces as well as microscale capillary action. In spinal cord injury (SCI) rats, HES–hAESCs promoted functional recovery and axonal projection by reducing neuroinflammation and improving the neurotrophic microenvironment surrounding the lesions. In summary, the dual driving forces model provides a new rationale for engineering hydrogel scaffolds to facilitate self‐promoted cell absorption. The HES platform demonstrates great potential as a powerful and efficient vehicle for delivering high densities of hAESCs to promote clinical treatment and repair of SCI.

100 项与人羊膜上皮干细胞(Shanghai iCELL Biotechnology) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
宫腔粘连	临床2期	中国	上海赛傲生物技术有限公司	2022-01-30
帕金森病	临床2期	中国	上海赛傲生物技术有限公司	2022-01-30
原发性卵巢功能不全	临床2期	中国	上海赛傲生物技术有限公司	2022-01-30
难治性急性移植物抗宿主病	临床2期	中国	上海赛傲生物技术有限公司	2022-01-30
急性移植物抗宿主病	临床1期	-	上海赛傲生物技术有限公司	2024-01-01
移植物抗宿主病	临床1期	中国	北京大学人民医院	2020-06-26
桥本病	临床前	中国	上海赛傲生物技术有限公司	2022-01-30
脊髓损伤	临床前	中国	上海赛傲生物技术有限公司	2022-01-30
系统性红斑狼疮	临床前	中国	上海赛傲生物技术有限公司	2022-01-30
葡萄膜炎	临床前	中国	上海赛傲生物技术有限公司	2022-01-30